Table 3.
Comparisons of Lymphocyte mRNA Values in Schizophrenics and Controls
| mRNA | Schizophrenics (CSZ) | Controls (NPC) | Test |
|---|---|---|---|
| DNMT | |||
| DNMT1 (or) | |||
| All Subjects | 128.92 ± 53.17 (n=29) | 115.21 ± 53.38 (n=31) | TL= −1.202, df=58, P=0.234 |
| Males | 136.65 ± 56.61 (n=22) | 101.45 ± 25.49 (n=19) | TL= 2.544, df=39, P=0.015* |
| Females | 104.61 ± 32.70 (n=7) | 136.98 ± 76.57 (n=12) | TL= 1.001, df=17, P=0.331 |
| DNMT1 (cus) | |||
| All Subjects | 13.69 ± 8.16 (n=38) | 10.83 ± 5.02 (n=33) | T= 1.746, df= 69, P=0.085 |
| Males | 14.38 ± 8.66 (n=31) | 10.05 ± 3.98 (n=22) | TU=2.446, df= 44.86, P=0.018 |
| Females | 10.65 ± 4.75 (n=7) | 12.41 ± 6.56 (n=11) | T=0.611, df= 16, P=0.550 |
| DNMT3A | |||
| All Subjects | 201.27 ± 83.28 (n=36) | 162.27 ± 48.76 (n =31) | TU=2.376, df= 57.73, P=0.021* |
| Males | 213.09 ± 86.81 (n=28) | 157.17 ± 42.46 (n=19) | TU=2.931, df= 41.63, P=0.005*A |
| Females | 159.90 ± 55.69 (n=8) | 170.35 ± 58.45 (n=12) | T= 0.399, df=18, P= 0.695 |
| GABAERGIC RELATED | |||
| GAD1 | |||
| All subjects | 0.24 ± 0.28 (n=36) | 0.083 ± 0.092 (n=31) | TUL=2.965, df=60.56, P=0.004*A |
| Males | 0.28 ± 0.30 (n=28) | 0.094 ± 0.11 (n=19) | TUL=2.749, df=45.00, P=.009* |
| Females | 0.12 ± 0.15 (n=8) | 0.065 ± 0.050 (n=12) | TL=0.700, df=18, P=0.493 |
| GAD67 | |||
| All subjects | Median 0.024 (n=37) | Median 0.019 (n=33) | MWU Z= 1.571, P=0.116b |
| Males | Median 0.035 (n=30) | Median 0.020 (n=22) | MWU Z= 1.741, P=0.082b |
| Females | Median 0.018 (n=7) | Median 0.019 (n=11) | MWU Z= −0.556, P= 0.596c |
| GAD25 | |||
| All subjects | 0.164 ± 0.322 (n=37) | 0.068 ± 0.106 (n=33) | TL= 1.623, df= 68, P= 0.109 |
| Males | 0.195 ± 0.351 (n=30) | 0.066 ± 0.085 (n= 22) | TL= 1.813, df= 50, P= 0.076 |
| Females | 0.032 ± 0.025 (n=7) | 0.074 ± 0.144 (n=11) | TL=0.718, df= 16, P= 0.483 |
| GAD25/GAD67 Ratio | |||
| All subjects | Median 1.65 (n=37) | Median 1.92 (n=33) | MWU Z= −1.171, P= 0.242c |
| Males | Median 1.52 (n=30) | Median 2.18 (n=22) | MWU Z=- 0.963, P=0.335c |
| Females | Median 1.76 (n=7) | Median 1.79 (n=11) | MWU Z= −0.618, P= 0.659c |
| TET | |||
| TET1 | |||
| All subjects | 28.26 ± 13.02 (n=36) | 26.71 ± 12.84 (n=31) | T= 0.487, df=65, P=0 .628 |
| Males | 29.42 ± 13.75 (n=28) | 28.76 ± 13.89 (n=19) | T= 0.161 df=45, P= 0.873 |
| Females | 24.18 ± 9.69 (n=8) | 23.47 ± 10.72 (n=12) | T= 0.151, df= 18, P=0.882 |
| TET2 | |||
| All subjects | 327.90 ± 128.82 (n=36) | 287.93 ± 145.45 (n=30) | T= 1.184, df= 64, P= 0.241 |
| Males | 327.87 ± 123.53(n=28) | 286.88 ± 108.14 (n=19) | T= 1.17, df=45, P= 0.247 |
| Females | 328.01 ± 155.52 (n=8) | 289.74 ± 200.74 (n=11) | T=−0.44, df=17, P=0. 659 |
| TET3 | |||
| All subjects | 194.97 ± 67.74 (n=36) | 164.45 ± 59.35 (n=31) | T=1.947, df= 65, P=0.056 |
| Males | 198.50 ± 66.67 (n=28) | 176.80 ± 57.32 (n=19) | T=1.157, df= 45, P=0.253 |
| Females | 182.62 ± 74.63 (n=8) | 144.88 ± 59.57 (n=12) | T= 0.449, df= 17, P=0.659 |
| Other Genes Expression Influenced by Methylation of CpG Targets of Promotor Gene | |||
| BDNF | |||
| BDNF (bs) | |||
| All subjects | 20.62 ± 8.45 (n=36) | 18.03 ± 11.67 (n=31) | TL= 1.593, df=65, P=0.116 |
| Males | 21.72 ± 9.10 (n=28) | 19.82 ± 14.38 (n=19) | TL= −1.074, df=45, P=0.289 |
| Females | 16.77 ± 4.00 (n=8) | 15.20 ± 4.36 (n=12) | TL= 0.887, df=18, P= 0.387 |
| BDNFIX | |||
| All subjects | 3.52 ± 2.32 (n=38) | 3.01 ± 2.22 (n=33) | TL= 1.373, df=69, P= 0.174 |
| Males | 3.79 ± 2.47 (n=31) | 2.93 ± 2.12 (n=22) | TL= 1.637, df=51, P= 0.108 |
| Females | 2.32 ± 0.81 (n=7) | 3.16 ± 2.51 (n=11) | TL= 0.52, df=16, P= 0.609 |
| GLUCOCORTICOID RECEPTOR | |||
| NR3C1(bc) | |||
| All subjects | 281.30 ± 117.50(n= 35) | 175.45 ± 89.50 (n=31) | TSR= 4.393, df=64, P<0. 001*A |
| Males | 288.02 ± 116.54 (n=27) | 168.61 ± 97.15 (n=19) | TSR= 4.157, df=44, P<0.001*A |
| Females | 258.6 ± 125.92(n=8) | 186.28 ± 78.69 (n=12) | TSR= 1.461, df=18, P= 0.161 |
| NR3C1 (cus) | |||
| All subjects | 144.26 ± 54.36 (n=38) | 119.25 ± 51.13 (n=33) | T= 1.988, df=69, P= 0.051 |
| Males | 148.01 ± 58.24 (n=31) | 119.31 ± 43.51 (n=22) | T= 1.954, df=51, P=0.056 |
| Females | 127.64 ± 29.49 (n=7) | 119.11 ± 66.25 (n=11) | T= .318, df=16, P= 0.754 |
| mRNA’s Which Were Preliminary Hits from RNA Sequence Analysis | |||
| FPRF3 | |||
| All subjects | 20.45 ± 22.78 (n=36) | 28.53 ± 20.97 (n=30) | TL= 2.276, df=64, P= 0.026 |
| Males | 20.29 ± 20.27 (n=28) | 30.29 ± 23.41 (n=18) | TL= 1.964, df= 44, P= 0.056 |
| Females | 20.98 ± 31.78 (n=8) | 25.88 ± 17.32 (n=12) | TL= 1.290, df=18, P= 0.213 |
| CD4 | |||
| All subjects | 139.22 ± 118.11 (n=35) | 124.64 ± 113.89 (n=30) | TL= 0.824, df=63, P= 0.413 |
| Males | 137.08 ± 127.37 (n=27) | 121.14 ± 89.48 (n=18) | TL= 0.402, df=44, P=0.689 |
| Females | 146.44 ± 86.16 (n=8) | 129.87 ± 147.56 (n=12) | TL=0.628, df=18, P= 0.435 |
| CCR1 | |||
| All subjects | Median 4.27 (n=36) | Median 6.95 (n=29) | MWU Z= 0.132, P= 0.895b |
| Males | Median 3.93 (n=28) | Median 6.61 (n=18) | MWU Z=−0.450, P= 0.653c |
| Females | Median 11.84 (n=8) | Median 7.00 (n=11) | MWU Z= 1.239, P= 0.215b |
| APPB2 | |||
| All subjects | 8.13 ± 7.93 (n=38) | 6.25 ± 5.30 (n=33) | TL=1.298, df=69, P=0.199 |
| Males | 8.22 ± 7.30 (n=31) | 6.61 ± 5.76 (n=22) | TL=1.117, df=51, P= 0.269 |
| Females | 7.78 ± 11.01 (n=7) | 5.52 ± 4.40 (n=11) | TL= 0.377, df= 16, P=0.711 |
| CPT1 | |||
| All subjects | 226.53 ± 174.22 (n=36) | 281.15 ± 211.04 (n=33) | T=1.176, df=67, P=0.244 |
| Males | 229.64 ± 180.02 (n=33) | 269.19 ± 229.24 (n=22) | T= 0.703, df=51, P=0. 485 |
| Females | 207.20 ± 148.33 (n=5) | 305.06 ± 176.69 (n=11) | T= 1.073, df= 14, P= 0.301 |
| CNTNAP2 | |||
| All subjects | 0.37 ± 1.15 (n=36) | 0.04 ± 0.05 (n=33) | TLU= 3.047, df= 59.10, P=0.003*A |
| Males | 0.44 ± 1.27 (n=29) | 0.04 ± 0.05 (n=22) | TLU= 3.126, df= 47.19, P=0.003*A |
| Females | 0.06 ± 0.08 (n=7) | 0.04 ± 0.07 (n=11) | TL=0.283, df= 16, P=0.781 |
| IMPA2 | |||
| All subjects | 38.38 ± 32.89 (n=36) | 26.10 ± 18.76 (n=33) | TSR= 1.603, df=67, P=0.114 |
| Males | 38.63 ± 33.30 (n=29) | 28.28 ± 18.92 (n=22) | TSR= 1.063, df= 49, P= 0.293 |
| Females | 37.37 ± 33.69 (n-7) | 21.74 ± 18.52 (n=11) | TSR= 1.007, df= 16, P= 0.329 |
Each number presents Mean ± S.D. For non-normal distributions analyzed by MWU test Median values are presented. Values are ddCt=2^(-dt) * 104; B-Actin was used as housekeeping gene. Values reported in the table are the original values, although for some tests the analysis T-test was performed on the normalized transformed (log, sq root) values. T=independent sample T-test, TL=independent samples t-test based on log transformed values; TU= independent samples T-Test for unequal variances, TSR=independent samples T-test based on square root transformed values, MWU=non-parametric test based on Mann-Whitey U.
*
statistically significant at BH corrected significance levels (α=.05) using 3 test comparison =i.e. for all subjects, males, females.
A
= statistically significant BH corrected significant levels (α=.05), when tests for 19 mRNAs were included in protected BH comparison test.
b
In MWU test mean rank of CSZ higher than NPC.
c
In MWU test mean rank of CSZ lower than NPC. For full picture of GAD67 mRNA values also see Figure S1 in supplement.